Advertisement

HRT in a new light: Thanks UK

      The recent excellent EMAS Consensus Statement [
      • Lambrinoudaki
      • et al.
      Menopause, wellbeing, and health: a care pathway from the European menopause and andropause society.
      ] clearly describes how menopausal hormone treatment is not a single entity; that is, different preparations with different characteristics and indications are available, suitable for different indications and preferences. Type, dose, and route of administration make the difference. This important concept has now been confirmed by a regulatory agency. For the very first time in Europe, a product listed among the notorious hormone replacement therapy (HRT) options is going to be available over the counter. The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has reviewed all the efficacy and safety evidence, and, with the collaboration of the British Menopause Society and the Royal College of Obstetricians and Gynaecologists, has announced that it has reclassified Gina 10 μg tablets (estradiol hemihydrate) from a prescription-only medicine to a pharmacy medicine. The change is due to come into effect in September 2022 [ ]. This is an epochal change. Low-dose vaginal estrogens have been widely used since the 1980s and are considered effective and safe for millions of women with severe symptoms that negatively impact their everyday life. Thus, an important national agency acknowledges that not all HRT products are the same. For the time being, this change concerns just one product, but, obviously, we are waiting for a similar revision for other low-dose local products containing either estriol, promestriene, or prasterone.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lambrinoudaki
        • et al.
        Menopause, wellbeing, and health: a care pathway from the European menopause and andropause society.
        Maturitas. 2022; 163: 1-14
        • Baber R.J.
        • Panay N.
        • A. Fenton the IMS Writing Group
        2016 IMS recommendations on women’s midlife health and menopause hormone therapy.
        Climacteric. 2016; 19: 109-150https://doi.org/10.3109/13697137.2015.1129166
        • The British Menopause Society &amp
        • Women’s Health Concern
        Recommendations on Hormone Replacement Therapy in Menopausal Women.
        2016
        • Cagnacci
        • et al.
        Recommendations on menopausal hormone replacement therapy.; executive Committee of the Italian Society of menopause (SIM) and of the italian Society of Gynecology of the third age (SIGiTE).
        Minerva Ginecol. 2019; 71: 395-403https://doi.org/10.23736/S0026-4784.19.04500-3
      1. The 2022 hormone therapy position statement of The North American Menopause Society.
        Menopause. 2022; 29: 767-794https://doi.org/10.1097/GME.0000000000002028
        • Hirschberg A.L.
        • Bitzer J.
        • Cano A.
        • Ceausu I.
        • Chedraui P.
        • Durmusoglu F.
        • Erkkola R.
        • Goulis D.G.
        • Kiesel L.
        • Lopes P.
        • Pines A.
        • van Trotsenburg M.
        • Lambrinoudaki I.
        • Maturitas Rees M.
        Topical Estrogens and Non-hormonal Preparations for Postmenopausal Vulvovaginal Atrophy: An EMAS Clinical Guide. 148. 2021 Jun: 55-61